Tumor-infiltrating Mesenchymal Stem Cells: Drivers of the Immunosuppressive Tumor Microenvironment in Prostate Cancer?

Overview

Journal Prostate

Date 2018 Nov 30

PMID 30488530

Citations 53

Authors

Timothy E Krueger

Daniel L J Thorek

Alan K Meeker

John T Isaacs

W Nathaniel Brennen

Affiliations

Soon will be listed here.

Abstract

Background: Prostate cancer is characterized by T-cell exclusion, which is consistent with their poor responses to immunotherapy. In addition, T-cells restricted to the adjacent stroma and benign areas are characterized by anergic and immunosuppressive phenotypes. In order for immunotherapies to produce robust anti-tumor responses in prostate cancer, this exclusion barrier and immunosuppressive microenvironment must first be overcome. We have previously identified mesenchymal stem cells (MSCs) in primary and metastatic human prostate cancer tissue.

Methods: An Opal Multiplex immunofluorescence assay based on CD73, CD90, and CD105 staining was used to identify triple-labeled MSCs in human prostate cancer tissue. T-cell suppression assays and flow cytometry were used to demonstrate the immunosuppressive potential of primary MSCs expanded from human bone marrow and prostate cancer tissue from independent donors.

Results: Endogenous MSCs were confirmed to be present at sites of human prostate cancer. These prostate cancer-infiltrating MSCs suppress T-cell proliferation in a dose-dependent manner similar to their bone marrow-derived counterparts. Also similar to bone marrow-derived MSCs, prostate cancer-infiltrating MSCs upregulate expression of PD-L1 and PD-L2 on their cell surface in the presence of IFNγ and TNFα.

Conclusion: Prostate cancer-infiltrating MSCs suppress T-cell proliferation similar to canonical bone marrow-derived MSCs, which have well-documented immunosuppressive properties with numerous effects on both innate and adaptive immune system function. Thus, we hypothesize that selective depletion of MSCs infiltrating sites of prostate cancer should restore immunologic recognition and elimination of malignant cells via broad re-activation of cytotoxic pro-inflammatory pathways.

Citing Articles

Immunome profiling in prostate cancer: a guide for clinicians.

San-Jose Manso L, Alfranca A, Moreno-Perez I, Ruiz-Vico M, Velasco C, Toquero P Front Immunol. 2024; 15:1398109.

PMID: 39635522 PMC: 11614818. DOI: 10.3389/fimmu.2024.1398109.

Mesenchymal stem/stromal cells: dedicator to maintain tumor homeostasis.

Yao J, Sun L, Gao F, Zhu W Hum Cell. 2024; 38(1):21.

PMID: 39607530 DOI: 10.1007/s13577-024-01154-y.

Unraveling the interplay between inflammation and stem cell mobilization or homing: Implications for tissue repair and therapeutics.

Chang H, Liou Y, Sun D Tzu Chi Med J. 2024; 36(4):349-359.

PMID: 39421490 PMC: 11483098. DOI: 10.4103/tcmj.tcmj_100_24.

Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance.

McClelland S, Maxwell P, Branco C, Barry S, Eberlein C, LaBonte M Cancers (Basel). 2024; 16(16).

PMID: 39199570 PMC: 11352248. DOI: 10.3390/cancers16162797.

Revisiting the role of mesenchymal stromal cells in cancer initiation, metastasis and immunosuppression.

Zhang Y, Wang C, Li J Exp Hematol Oncol. 2024; 13(1):64.

PMID: 38951845 PMC: 11218091. DOI: 10.1186/s40164-024-00532-4.

References

Brennen W, Denmeade S, Isaacs J . Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer. 2013; 20(5):R269-90. PMC: 3994592. DOI: 10.1530/ERC-13-0151. View

Munn D, Bronte V . Immune suppressive mechanisms in the tumor microenvironment. Curr Opin Immunol. 2015; 39:1-6. PMC: 5627973. DOI: 10.1016/j.coi.2015.10.009. View

Kiessling A, Wehner R, Fussel S, Bachmann M, Wirth M, Schmitz M . Tumor-associated antigens for specific immunotherapy of prostate cancer. Cancers (Basel). 2013; 4(1):193-217. PMC: 3712678. DOI: 10.3390/cancers4010193. View

Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M . IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature. 2018; 559(7714):363-369. PMC: 6461206. DOI: 10.1038/s41586-018-0266-0. View

Nakata W, Nakai Y, Yoshida T, Sato M, Hatano K, Nagahara A . Bone marrow-derived cells contribute to regeneration of injured prostate epithelium and stroma. Prostate. 2015; 75(8):806-14. DOI: 10.1002/pros.22962. View

Brennen W, Isaacs J, Denmeade S . Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther. 2012; 11(2):257-66. PMC: 3586189. DOI: 10.1158/1535-7163.MCT-11-0340. View

Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F . Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther. 2008; 15(10):730-8. DOI: 10.1038/gt.2008.39. View

De Marzo A, Platz E, Sutcliffe S, Xu J, Gronberg H, Drake C . Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007; 7(4):256-69. PMC: 3552388. DOI: 10.1038/nrc2090. View

English K, Ryan J, Tobin L, Murphy M, Barry F, Mahon B . Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol. 2009; 156(1):149-60. PMC: 2673753. DOI: 10.1111/j.1365-2249.2009.03874.x. View

10.

Linju Yen B, Yen M, Hsu P, Liu K, Wang C, Bai C . Multipotent human mesenchymal stromal cells mediate expansion of myeloid-derived suppressor cells via hepatocyte growth factor/c-met and STAT3. Stem Cell Reports. 2013; 1(2):139-51. PMC: 3757753. DOI: 10.1016/j.stemcr.2013.06.006. View

11.

Helmink B, Gaudreau P, Wargo J . Immune Checkpoint Blockade across the Cancer Care Continuum. Immunity. 2018; 48(6):1077-1080. DOI: 10.1016/j.immuni.2018.06.003. View

12.

Bergfeld S, DeClerck Y . Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 2010; 29(2):249-61. DOI: 10.1007/s10555-010-9222-7. View

13.

Su J, Chen X, Huang Y, Li W, Li J, Cao K . Phylogenetic distinction of iNOS and IDO function in mesenchymal stem cell-mediated immunosuppression in mammalian species. Cell Death Differ. 2013; 21(3):388-96. PMC: 3921585. DOI: 10.1038/cdd.2013.149. View

14.

Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D . Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353(12):1224-35. DOI: 10.1056/NEJMoa051931. View

15.

Olson B, McNeel D . Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer. Prostate. 2007; 67(16):1729-39. DOI: 10.1002/pros.20652. View

16.

Yuan H, Hsiao Y, Zhang Y, Wang J, Yin C, Shen R . Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion. BMC Cancer. 2013; 13:258. PMC: 3722065. DOI: 10.1186/1471-2407-13-258. View

17.

Zlotta A, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M . Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst. 2013; 105(14):1050-8. DOI: 10.1093/jnci/djt151. View

18.

Klopp A, Gupta A, Spaeth E, Andreeff M, Marini 3rd F . Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem Cells. 2011; 29(1):11-9. PMC: 3059412. DOI: 10.1002/stem.559. View

19.

Caplan A, Correa D . The MSC: an injury drugstore. Cell Stem Cell. 2011; 9(1):11-5. PMC: 3144500. DOI: 10.1016/j.stem.2011.06.008. View

20.

Roberts E, Deonarine A, Jones J, Denton A, Feig C, Lyons S . Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 2013; 210(6):1137-51. PMC: 3674708. DOI: 10.1084/jem.20122344. View